Henry Schein appoints KKR partner Max Lin to board; removes KKR voting commitment

HENRY SCHEIN INC

Max Lin, a KKR partner and head of Americas Health Care Private Equity, appointed to board effective May 2, 2025.
Board size increased to 15 directors; Lin will serve on Nominating/Governance and Strategic Advisory committees.
Regulatory conditions (HSR, Sweden/Italy approvals) for Lin's appointment satisfied as of April 10, 2025.
Lin receives standard non-employee director cash compensation (payable to KKR) but no equity grants.
Letter agreement deletes Section 5.11 of the KKR Strategic Partnership Agreement, removing investor's voting commitment.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Max Lin

Director

HSIC · HENRY SCHEIN INC

Effective: 2025-05-02
Filed: May 2, 2025, 7:59 PM ET

On May 2, 2025, Max Lin was appointed to the Company’s board of directors (the “ Board ”) as a director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Max Lin was appointed as Director at HENRY SCHEIN INC.

Action: appointed
Role: Director

Exact text from the filing

On May 2, 2025, Max Lin was appointed to the Company’s board of directors (the “ Board ”) as a director.

View on SEC.gov

HENRY SCHEIN INC filing history →

Source: SEC EDGAR

accession 0001193125-25-111677

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.